Key result
Prostate radiation therapy was associated with the development of radiation-associated hypertension in 47.4% (36 of 76) of patients, with 27% requiring additional anti-hypertensive medication.
Why the study?
Patients undergoing prostate radiation therapy were observed to have elevated blood pressures in clinic, motivating further characterisation of this phenomenon.
Does prostate radiation therapy cause radiation-associated hypertension in patients with prostate cancer?
Cohort (n=76)
Does prostate radiation therapy cause radiation-associated hypertension in patients with prostate cancer?
A significant proportion of patients undergoing prostate radiotherapy develop radiation-associated hypertension, necessitating blood pressure monitoring and potential medical management.
Answers are grounded in this paper and cite their sources.
May support BP monitoring after prostate radiation; Level 3 data leaves open causality and practice change.
OBJECTIVE: Patients undergoing prostate radiation therapy were observed to have elevated blood pressures in clinic. Therefore, we sought to further characterise this phenomenon. METHODS: The charts of 76 patients who received radiotherapy for prostate cancer between 2014 and 2017 were examined. Blood pressure (BP) readings were obtained at initial consultation, on treatment visits, and subsequent follow-up appointments. To describe this effect, we defined radiation-associated hypertension (RAH) as an increase ≥15 mmHg systolic BP, 10 mmHg diastolic BP, or 5 mmHg mean arterial pressure. RESULTS: Within this cohort, 36 patients developed RAH, with 75% developing RAH while on treatment, and 25% developing RAH at post-treatment visits. Two-thirds of patients remained hypertensive during post-treatment visits, and 27% were prescribed additional anti-hypertensives. There was no association between neoadjuvant/concurrent androgen deprivation therapy and RAH. CONCLUSION: A significant number of patients undergoing prostate radiotherapy developed RAH, necessitating additional medication in some.
No takes yet. Share an insight, caveat, or question.
Farrugia et al. (2019) conducted a cohort in Prostate cancer (n=76). Prostate radiation therapy was evaluated on Radiation-associated hypertension (RAH) defined as an increase ≥15 mmHg systolic BP, 10 mmHg diastolic BP, or 5 mmHg mean arterial pressure. Prostate radiation therapy was associated with the development of radiation-associated hypertension in 47.4% (36 of 76) of patients, with 27% requiring additional anti-hypertensive medication.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: